Author

Yuki Nishida

The University of Texas MD Anderson Cancer CenterORCID 0000-0001-5827-7406Unclaimed ORCID profile · follow to get notified of new preprints

Additional preprints under this name without ORCID

Yuki Nishida1 paper · Okayama University

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Assay:proteomics· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell-cell communication· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Approach:machine learning (classical)· 1 Approach:microscopy & imaging analysis· 1

Frequent Co-Authors

Andrea D. BedoyiD· 2 shared Edward AyoubiD· 2 shared Koji SasakiiD· 2 shared Michael AndreeffiD· 2 shared Abhishek MaitiiD· 1 shared Akshay BasiiD· 1 shared Bing Z. CarteriD· 1 shared Darah A Scruggs· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 40 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Andrea D. BedoyORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivPreprintMay 19, 2026

Niche-level immune evasion in TP53 mutant AML residual disease revealed by spatial proteomics

Mizuno Hideaki, Yuki Nishida, Andrea D. Bedoy…·Michael Andreeff

This study uses spatial proteomics to reveal that TP53 mutant AML residual disease forms immunosuppressive niches in the bone marrow, segregated from T-cells, suggesting niche-level immune evasion.

DOI 10.64898/2026.05.15.725421

humanspatial transcriptomics

𝕏 PostBluesky

Cancer BiologybioRxivPreprintApr 24, 2025

Dual MYC and GSPT1 Protein Degrader for MYC-Driven Cancers

Yuki Nishida, Valeria Impedovo, Edward Ayoub…·Michael Andreeff

This paper identifies a novel MYC-GSPT1 feedback loop and reports a dual degrader, GT19630, that effectively targets MYC-driven cancers with anti-proliferative and apoptotic effects.

DOI 10.1101/2025.04.24.650490

humanproteomics

𝕏 PostBluesky